Comparison · NCT01966471-deaths
Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane vs Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane vs Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab: deaths from any cause. Trial comparisons, record NCT01966471-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01966471-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0486 | 0.0365 | 0.0644 | wilson | |
| Risk in group 2 | 0.0603 | 0.0466 | 0.0777 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0117 | -0.0329 | 0.0092 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.806 | 0.549 | 1.18 | log | |
| Odds ratio, group 1 over group 2 | 0.796 | 0.531 | 1.19 | log | |
| Number needed to treat, for one fewer death from any cause on Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane than on Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | 85.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane | Trastuzumab and pertuzumab were administered concurrently for up to a total duration of 1 year (up to 18 cycles \[1 Cycle = 21 days\]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline \[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\] based chemotherapy. | 45 | 926 | EG000 |
| Group 2 | Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab | Trastuzumab emtansine and pertuzumab continued for up to a total duration of 1 year (up to 18 cycles \[1 Cycle = 21 days\]) following anthracycline \[5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)\] based chemotherapy. | 55 | 912 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From randomization to approximately 7.5 years
Source ClinicalTrials.gov
Trial
- Title
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
- NCT number
- NCT01966471
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2021-01-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01966471?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01966471-deaths